Literature DB >> 22618028

Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Gilson S Baia1, Otavia L Caballero, Brent A Orr, Anita Lal, Janelle S Y Ho, Cynthia Cowdrey, Tarik Tihan, Christian Mawrin, Gregory J Riggins.   

Abstract

The Hippo signaling pathway is functionally conserved in Drosophila melanogaster and mammals, and its proposed function is to control tissue homeostasis by regulating cell proliferation and apoptosis. The core components are composed of a kinase cascade that culminates with the phosphorylation and inhibition of Yes-associated protein 1 (YAP1). Phospho-YAP1 is retained in the cytoplasm. In the absence of Hippo signaling, YAP1 translocates to the nucleus, associates with co-activators TEAD1-4, and functions as a transcriptional factor promoting the expression of key target genes. Components of the Hippo pathway are mutated in human cancers, and deregulation of this pathway plays a role in tumorigenesis. Loss of the NF2 tumor suppressor gene is the most common genetic alteration in meningiomas, and the NF2 gene product, Merlin, acts upstream of the Hippo pathway. Here, we show that primary meningioma tumors have high nuclear expression of YAP1. In meningioma cells, Merlin expression is associated with phosphorylation of YAP1. Using an siRNA transient knockdown of YAP1 in NF2-mutant meningioma cells, we show that suppression of YAP1 impaired cell proliferation and migration. Conversely, YAP1 overexpression led to a strong augment of cell proliferation and anchorage-independent growth and restriction of cisplatin-induced apoptosis. In addition, expression of YAP1 in nontransformed arachnoidal cells led to the development of tumors in nude mice. Together, these findings suggest that in meningiomas, deregulation of the Hippo pathway is largely observed in primary tumors and that YAP1 functions as an oncogene promoting meningioma tumorigenesis. Mol Cancer Res; 10(7); 904-13. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22618028      PMCID: PMC4703097          DOI: 10.1158/1541-7786.MCR-12-0116

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

1.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

2.  Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth.

Authors:  Brent A Orr; Haibo Bai; Yazmin Odia; Deepali Jain; Robert A Anders; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

3.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.

Authors:  X Zhang; J George; S Deb; J L Degoutin; E A Takano; S B Fox; D D L Bowtell; K F Harvey
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

4.  Establishment of a human malignant meningioma cell line with amplified c-myc oncogene.

Authors:  K Tanaka; C Sato; Y Maeda; M Koike; M Matsutani; K Yamada; M Miyaki
Journal:  Cancer       Date:  1989-12-01       Impact factor: 6.860

5.  Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases.

Authors:  A Perry; C Giannini; R Raghavan; B W Scheithauer; R Banerjee; L Margraf; D C Bowers; R A Lytle; I F Newsham; D H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2001-10       Impact factor: 3.685

6.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression.

Authors:  S A Rempel; K Schwechheimer; R L Davis; W K Cavenee; M L Rosenblum
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

8.  salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines.

Authors:  Nicolas Tapon; Kieran F Harvey; Daphne W Bell; Doke C R Wahrer; Taryn A Schiripo; Daniel A Haber; Iswar K Hariharan
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

9.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.

Authors:  Y Sekido; H I Pass; S Bader; D J Mew; M F Christman; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

10.  A human brainstem glioma xenograft model enabled for bioluminescence imaging.

Authors:  Rintaro Hashizume; Tomoko Ozawa; Eduard B Dinca; Anuradha Banerjee; Michael D Prados; Charles D James; Nalin Gupta
Journal:  J Neurooncol       Date:  2009-07-08       Impact factor: 4.130

View more
  26 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

Review 2.  Recent Advances of the Hippo/YAP Signaling Pathway in Brain Development and Glioma.

Authors:  Taohui Ouyang; Wei Meng; Meihua Li; Tao Hong; Na Zhang
Journal:  Cell Mol Neurobiol       Date:  2019-11-25       Impact factor: 5.046

3.  LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.

Authors:  Chao Guo; Xintian Wang; Lufeng Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.

Authors:  EeeLN H Buckarma; Nathan W Werneburg; Caitlin B Conboy; Ayano Kabashima; Daniel R O'Brien; Chen Wang; Sumera Rizvi; Rory L Smoot
Journal:  Mol Cancer Res       Date:  2020-07-09       Impact factor: 5.852

Review 5.  Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects.

Authors:  Yong-Chang Liu; Yan-zhou Wang
Journal:  Tumour Biol       Date:  2015-03-07

6.  Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.

Authors:  Christine G Skibinski; Tara Williamson; Gregory J Riggins
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

7.  The Hippo signaling pathway and translational opportunities for brain cancers.

Authors:  Gilson S Baia; Otavia L Caballero; Gregory J Riggins
Journal:  CNS Oncol       Date:  2012-11

Review 8.  Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.

Authors:  Wei Kang; Alfred S L Cheng; Jun Yu; Ka Fai To
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

9.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

10.  Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.

Authors:  A S Yamashita; G S Baia; J S Y Ho; E Velarde; J Wong; G L Gallia; A J Belzberg; E T Kimura; G J Riggins
Journal:  J Neurooncol       Date:  2014-03-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.